Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry

Journal of Medicinal Chemistry

Volumn 60, Issue 10, 2017, Pages 4126-4134

  Fronik, Philipp ^a   Gaiser, Birgit I ^a   Sejer Pedersen, Daniel ^b  

^a University of Copenhagen ^*

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; MUSCARINIC RECEPTOR;

ALLOSTERIC SITE; ALLOSTERISM; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CONFORMATION; HUMAN; LIGAND BINDING; MEDICINAL CHEMISTRY; MOLECULAR MODEL; PARTIAL AGONISM; PHARMACOPHORE; PROTEIN TARGETING; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; PROCEDURES;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; BINDING SITES; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85019767390     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01601     Document Type: Article

References (93)

1. Stevens, R. C.; Cherezov, V.; Katritch, V.; Abagyan, R.; Kuhn, P.; Rosen, H.; Wüthrich, K. The GPCR network: a large-scale collaboration to determine human GPCR structure and function Nat. Rev. Drug Discovery 2013, 12, 25-34 10.1038/nrd3859
2. Fredriksson, R.; Lagerström, M. C.; Lundin, L. G.; Schiöth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Mol. Pharmacol. 2003, 63, 1256-1272 10.1124/mol.63.6.1256
3. Katritch, V.; Cherezov, V.; Stevens, R. C. Structure-function of the G protein-coupled receptor superfamily Annu. Rev. Pharmacol. Toxicol. 2013, 53, 531-556 10.1146/annurev-pharmtox-032112-135923
4. Lagerström, M. C.; Schiöth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery Nat. Rev. Drug Discovery 2008, 7, 339-357 10.1038/nrd2518
5. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discovery 2006, 5, 993-996 10.1038/nrd2199
6. Wootten, D.; Christopoulos, A.; Sexton, P. M. Emerging paradigms in GPCR allostery: implications for drug discovery Nat. Rev. Drug Discovery 2013, 12, 630-644 10.1038/nrd4052
7. Lane, J. R.; Abdul-Ridha, A.; Canals, M. Regulation of G protein-coupled receptors by allosteric ligands ACS Chem. Neurosci. 2013, 4, 527-534 10.1021/cn400005t
8. Bradley, S. J.; Tobin, A. B. Design of next-generation G protein-coupled receptor drugs: linking novel pharmacology and in vivo animal models Annu. Rev. Pharmacol. Toxicol. 2016, 56, 535-559 10.1146/annurev-pharmtox-011613-140012
9. Christopoulos, A. Advances in GPCR allostery: from function to structure Mol. Pharmacol. 2014, 86, 463-478 10.1124/mol.114.094342
10. Feng, Z.; Hu, G.; Ma, S.; Xie, X. Q. Computational advances for the development of allosteric modulators and bitopic ligands in G protein-coupled receptors AAPS J. 2015, 17, 1080-1095 10.1208/s12248-015-9776-y
11. Gentry, P. R.; Sexton, P. M.; Christopoulos, A. Novel allosteric modulators of G protein-coupled receptors J. Biol. Chem. 2015, 290, 19478-19488 10.1074/jbc.R115.662759
12. Mohr, K.; Schmitz, J.; Schrage, R.; Tränkle, C.; Holzgrabe, U. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G-protein coupled receptors Angew. Chem., Int. Ed. 2013, 52, 508-516 10.1002/anie.201205315
13. Soriano-Ursúa, M. A.; Trujillo-Ferrara, J. G.; Arias-Montaño, J. A.; Villalobos-Molina, R. Insights into a defined secondary binding region on β-adrenoceptors and putative roles in ligand binding and drug design MedChemComm 2015, 6, 991-1002 10.1039/C5MD00011D
14. Baltos, J. A.; Gregory, K. J.; White, P. J.; Sexton, P. M.; Christopoulos, A.; May, L. T. Quantification of adenosine A1 receptor biased agonism: Implications for drug discovery Biochem. Pharmacol. 2016, 99, 101-112 10.1016/j.bcp.2015.11.013
15. 1 muscarinic acetylcholine receptor Mol. Pharmacol. 2013, 84, 425-437 10.1124/mol.113.087320
16. Dror, R. O.; Pan, A. C.; Arlow, D. H.; Borhani, D. W.; Maragakis, P.; Shan, Y.; Xu, H.; Shaw, D. E. Pathway and mechanism of drug binding to G-protein-coupled receptors Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 13118-13123 10.1073/pnas.1104614108
17. González, A.; Perez-Acle, T.; Pardo, L.; Deupi, X. Molecular basis of ligand dissociation in β-adrenergic receptors PLoS One 2011, 6, e23815 10.1371/journal.pone.0023815
18. Buch, I.; Giorgino, T.; De Fabritiis, G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 10184-10189 10.1073/pnas.1103547108
19. Paoletta, S.; Sabbadin, D.; von Kügelgen, I.; Hinz, S.; Katritch, V.; Hoffmann, K.; Abdelrahman, A.; Straßburger, J.; Baqi, Y.; Zhao, Q.; Stevens, R. C.; Moro, S.; Müller, C. E.; Jacobson, K. A. Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information J. Comput.-Aided Mol. Des. 2015, 29, 737-756 10.1007/s10822-015-9858-z
20. 2A adenosine receptor as a key study J. Chem. Inf. Model. 2014, 54, 169-183 10.1021/ci400532b
21. 2A adenosine receptor of the endogenous agonist adenosine using supervised molecular dynamics simulations MedChemComm 2015, 6, 1081-1085 10.1039/C5MD00016E
22. Adam, D.; Kessler, U.; Kronke, M. Cross-linking of the p55 tumor necrosis factor receptor cytoplasmic domain by a dimeric ligand induces nuclear factor-kappa B and mediates cell death J. Biol. Chem. 1995, 270, 17482-17487
23. Ho, S. N.; Biggar, S. R.; Spencer, D. M.; Schreiber, S. L.; Crabtree, G. R. Dimeric ligands define a role for transcriptional activation domains in reinitiation Nature 1996, 382, 822-826 10.1038/382822a0
24. Gangloff, M.; Murali, A.; Xiong, J.; Arnot, C. J.; Weber, A. N.; Sandercock, A. M.; Robinson, C. V.; Sarisky, R.; Holzenburg, A.; Kao, C.; Gay, N. J. Structural insight into the mechanism of activation of the toll receptor by the dimeric ligand Spätzle J. Biol. Chem. 2008, 283, 14629-14635 10.1074/jbc.M800112200
25. Portoghese, P. S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists Trends Pharmacol. Sci. 1989, 10, 230-235 10.1016/0165-6147(89)90267-8
26. Hiller, C.; Kühhorn, J.; Gmeiner, P. Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands J. Med. Chem. 2013, 56, 6542-6559 10.1021/jm4004335
27. Huang, G.; Nimczick, M.; Decker, M. Rational modification of the biological profile of GPCR ligands through combination with other biologically active moieties Arch. Pharm. 2015, 348, 531-540 10.1002/ardp.201500079
28. 2-adrenergic and adenosine A1 receptor ligands J. Med. Chem. 2008, 51, 6128-6137 10.1021/jm800613s
29. Lane, J. R.; Sexton, P. M.; Christopoulos, A. Bridging the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol. Sci. 2013, 34, 59-66 10.1016/j.tips.2012.10.003
30. Aurelio, L.; Valant, C.; Flynn, B. L.; Sexton, P. M.; Christopoulos, A.; Scammells, P. J. Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes J. Med. Chem. 2009, 52, 4543-4547 10.1021/jm9002582
31. 1 acetylcholine receptor J. Med. Chem. 2015, 58, 560-576 10.1021/jm500860w
32. Antony, J.; Kellershohn, K.; Mohr-Andrä, M.; Kebig, A.; Prilla, S.; Muth, M.; Heller, E.; Disingrini, T.; Dallanoce, C.; Bertoni, S.; Schrobang, J.; Tränkle, C.; Kostenis, E.; Christopoulos, A.; Höltje, H. D.; Barocelli, E.; De Amici, M.; Holzgrabe, U.; Mohr, K. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity FASEB J. 2009, 23, 442-450 10.1096/fj.08-114751
33. Kruse, A. C.; Kobilka, B. K.; Gautam, D.; Sexton, P. M.; Christopoulos, A.; Wess, J. Muscarinic acetylcholine receptors: novel opportunities for drug development Nat. Rev. Drug Discovery 2014, 13, 549-560 10.1038/nrd4295
34. Roszkowski, A. P. An unusual type of sympathetic ganglionic stimulant J. Pharmacol. Exp. Ther. 1961, 132, 156-170
35. Birdsall, N. J.; Burgen, A. S.; Hulme, E. C.; Stockton, J. M.; Zigmond, M. J. The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart Br. J. Pharmacol. 1983, 78, 257-259 10.1111/j.1476-5381.1983.tb09388.x
36. Valant, C.; Gregory, K. J.; Hall, N. E.; Scammells, P. J.; Lew, M. J.; Sexton, P. M.; Christopoulos, A. A novel mechanism of G protein-coupled receptor functional selectivity J. Biol. Chem. 2008, 283, 29312-29321 10.1074/jbc.M803801200
37. 1muscarinic receptor Mol. Pharmacol. 2002, 61, 1297-1302 10.1124/mol.61.6.1297
38. 1 muscarinic receptor agonist, 77-LH-28-1 Br. J. Pharmacol. 2008, 154, 1104-1115 10.1038/bjp.2008.152
39. 1 agonist derived from the MLPCN probe ML071 Bioorg. Med. Chem. Lett. 2011, 21, 6451-6455 10.1016/j.bmcl.2011.08.084
40. 1 receptor function in the central nervous system ACS Chem. Neurosci. 2010, 1, 104-121 10.1021/cn900003h
41. 1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 2008, 28, 10422-10433 10.1523/JNEUROSCI.1850-08.2008
42. 2 muscarinic receptor Mol. Pharmacol. 2007, 72, 291-302 10.1124/mol.106.033746
43. Valant, C.; May, L. T.; Aurelio, L.; Chuo, C. H.; White, P. J.; Baltos, J. A.; Sexton, P. M.; Scammells, P. J.; Christopoulos, A. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 4614-4619 10.1073/pnas.1320962111
44. 1 muscarinic acetylcholine receptor Mol. Pharmacol. 2010, 78, 94-104 10.1124/mol.110.064345
45. 1 receptors J. Med. Chem. 2012, 55, 2125-2143 10.1021/jm201348t
46. 1 muscarinic receptors by bitopic fluorescent ligands Mol. Pharmacol. 2013, 84, 71-85 10.1124/mol.113.085670
47. 1 agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode ACS Chem. Neurosci. 2012, 3, 1025-1036 10.1021/cn300103e
48. 1 muscarinic acetylcholine receptor Bioorg. Med. Chem. Lett. 2012, 22, 3467-3472 10.1016/j.bmcl.2012.03.088
49. 1 muscarinic acetylcholine receptor J. Biol. Chem. 2014, 289, 23817-23837 10.1074/jbc.M114.582874
50. 2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias J. Biol. Chem. 2010, 285, 7459-7474 10.1074/jbc.M109.094011
51. 4 muscarinic acetylcholine receptor J. Biol. Chem. 2010, 285, 19012-19021 10.1074/jbc.M110.125096
52. Disingrini, T.; Muth, M.; Dallanoce, C.; Barocelli, E.; Bertoni, S.; Kellershohn, K.; Mohr, K.; De Amici, M.; Holzgrabe, U. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors J. Med. Chem. 2006, 49, 366-372 10.1021/jm050769s
53. Bonifazi, A.; Yano, H.; Del Bello, F.; Farande, A.; Quaglia, W.; Petrelli, R.; Matucci, R.; Nesi, M.; Vistoli, G.; Ferré, S.; Piergentili, A. Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) J. Med. Chem. 2014, 57, 9065-9077 10.1021/jm501173q
54. Bock, A.; Merten, N.; Schrage, R.; Dallanoce, C.; Bätz, J.; Klöckner, J.; Schmitz, J.; Matera, C.; Simon, K.; Kebig, A.; Peters, L.; Müller, A.; Schrobang-Ley, J.; Tränkle, C.; Hoffmann, C.; De Amici, M.; Holzgrabe, U.; Kostenis, E.; Mohr, K. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling Nat. Commun. 2012, 3, 1044 10.1038/ncomms2028
55. Schmitz, J.; van der Mey, D.; Bermudez, M.; Klöckner, J.; Schrage, R.; Kostenis, E.; Tränkle, C.; Wolber, G.; Mohr, K.; Holzgrabe, U. Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity J. Med. Chem. 2014, 57, 6739-6750 10.1021/jm500790x
56. Romagnoli, R.; Baraldi, P. G.; IJzerman, A. P.; Massink, A.; Cruz-Lopez, O.; Lopez-Cara, L. C.; Saponaro, G.; Preti, D.; Aghazadeh Tabrizi, M.; Baraldi, S.; Moorman, A. R.; Vincenzi, F.; Borea, P. A.; Varani, K. Synthesis and biological evaluation of novel allosteric enhancers of the A1 adenosine receptor based on 2-amino-3-(4′-chlorobenzoyl)-4-substituted-5-arylethynyl thiophene J. Med. Chem. 2014, 57, 7673-7686 10.1021/jm5008853
57. Narlawar, R.; Lane, J. R.; Doddareddy, M.; Lin, J.; Brussee, J.; IJzerman, A. P. Hybrid ortho/allosteric ligands for the adenosine A1 receptor J. Med. Chem. 2010, 53, 3028-3037 10.1021/jm901252a
58. Beaulieu, J. M.; Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors Pharmacol. Rev. 2011, 63, 182-217 10.1124/pr.110.002642
59. 3 receptors in drug addiction: a review of pharmacological evidence Brain Res. Rev. 2005, 49, 77-105 10.1016/j.brainresrev.2004.12.033
60. 3 receptor antagonists as therapeutic agents Drug Discovery Today 2005, 10, 917-925 10.1016/S1359-6446(05)03491-4
61. 3 receptor partial agonist and antagonist as potential drug abuse therapeutic agents J. Med. Chem. 2005, 48, 3663-3679 10.1021/jm040190e
62. Lane, J. R.; Donthamsetti, P.; Shonberg, J.; Draper-Joyce, C. J.; Dentry, S.; Michino, M.; Shi, L.; López, L.; Scammells, P. J.; Capuano, B.; Sexton, P. M.; Javitch, J. A.; Christopoulos, A. A new mechanism of allostery in a G protein-coupled receptor dimer Nat. Chem. Biol. 2014, 10, 745-752 10.1038/nchembio.1593
63. 3 receptor antagonist with high oral bioavailability and CNS penetration in the rat J. Med. Chem. 2000, 43, 1878-1885 10.1021/jm000090i
64. 2 receptor through fragmentation of a bitopic ligand J. Med. Chem. 2015, 58, 6819-6843 10.1021/acs.jmedchem.5b00585
65. 2 receptor J. Med. Chem. 2015, 58, 5287-5307 10.1021/acs.jmedchem.5b00581
66. 3 receptor antagonists J. Med. Chem. 2009, 52, 2559-2570 10.1021/jm900095y
67. Vass, M.; Agai-Csongor, E.; Horti, F.; Keserü, G. M. Multiple fragment docking and linking in primary and secondary pockets of dopamine receptors ACS Med. Chem. Lett. 2014, 5, 1010-1014 10.1021/ml500201u
68. 3 selective antagonist Science 2010, 330, 1091 10.1126/science.1197410
69. 3 receptors Mol. Pharmacol. 2013, 84, 854 10.1124/mol.113.087833
70. 3 dopamine receptor-selective antagonists Eur. Neuropsychopharmacol. 2015, 25, 1448-1461 10.1016/j.euroneuro.2014.11.013
71. 3 receptor ligands Bioorg. Med. Chem. 2016, 24, 191-200 10.1016/j.bmc.2015.12.002
72. 3 receptors Mol. Pharmacol. 2013, 84, 854-864 10.1124/mol.113.087833
73. Newman, A. H.; Beuming, T.; Banala, A. K.; Donthamsetti, P.; Pongetti, K.; Labounty, A.; Levy, B.; Cao, J.; Michino, M.; Luedtke, R. R.; Javitch, J.; Shi, L. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor J. Med. Chem. 2012, 55, 6689-6699 10.1021/jm300482h
74. 3 regulation of mouse cardiac conduction Mol. Pharmacol. 2016, 89, 176-186 10.1124/mol.115.100222
75. Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.; Aradhye, S.; Burtin, P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat. Rev. Drug Discovery 2010, 9, 883-897 10.1038/nrd3248
76. 3 receptor ACS Chem. Biol. 2012, 7, 1975-1983 10.1021/cb300392z
77. Decherchi, S.; Berteotti, A.; Bottegoni, G.; Rocchia, W.; Cavalli, A. The ligand binding mechanism to purine nucleoside phosphorylase elucidated via molecular dynamics and machine learning Nat. Commun. 2015, 6, 6155 10.1038/ncomms7155
78. Kappel, K.; Miao, Y.; McCammon, J. A. Accelerated molecular dynamics simulations of ligand binding to a muscarinic G-protein-coupled receptor Q. Rev. Biophys. 2015, 48, 479-487 10.1017/S0033583515000153
79. 3 muscarinic acetylcholine receptor Nature 2012, 482, 552-556 10.1038/nature10867
80. Shan, Y.; Kim, E. T.; Eastwood, M. P.; Dror, R. O.; Seeliger, M. A.; Shaw, D. E. How does a drug molecule find its target binding site ? J. Am. Chem. Soc. 2011, 133, 9181-9183 10.1021/ja202726y
81. Spiliotopoulos, D.; Caflisch, A. Molecular dynamics simulations of bromodomains reveal binding-site flexibility and multiple binding modes of the natural ligand acetyl-lysine Isr. J. Chem. 2014, 54, 1084-1092 10.1002/ijch.201400009
82. Hasenhuetl, P. S.; Schicker, K.; Koenig, X.; Li, Y.; Sarker, S.; Stockner, T.; Sucic, S.; Sitte, H. H.; Freissmuth, M.; Sandtner, W. Ligand selectivity among the dopamine and serotonin transporters specified by the forward binding reaction Mol. Pharmacol. 2015, 88, 12-18 10.1124/mol.115.099036
83. Kass, I.; Buckle, A. M.; Borg, N. Understanding the structural dynamics of TCR-pMHC complex interactions Trends Immunol. 2014, 35, 604-612 10.1016/j.it.2014.10.005
84. 1 receptor Biochemistry 1999, 38, 3498-3507 10.1021/bi982369v
85. Cooke, R. M.; Brown, A. J. H.; Marshall, F. H.; Mason, J. S. Structures of G protein-coupled receptors reveal new opportunities for drug discovery Drug Discovery Today 2015, 20, 1355-1364 10.1016/j.drudis.2015.08.003
86. 2 adrenergic G-protein-coupled receptor Nature 2007, 450, 383-387 10.1038/nature06325
87. 4R, observed by unconstrained molecular dynamics Bioorg. Med. Chem. Lett. 2015, 25, 1259-1268 10.1016/j.bmcl.2015.01.052
88. Dror, R. O.; Green, H. F.; Valant, C.; Borhani, D. W.; Valcourt, J. R.; Pan, A. C.; Arlow, D. H.; Canals, M.; Lane, J. R.; Rahmani, R.; Baell, J. B.; Sexton, P. M.; Christopoulos, A.; Shaw, D. E. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs Nature 2013, 503, 295-299 10.1038/nature12595
89. Sandal, M.; Behrens, M.; Brockhoff, A.; Musiani, F.; Giorgetti, A.; Carloni, P.; Meyerhof, W. Evidence for a transient additional ligand binding site in the TAS2R46 bitter taste receptor J. Chem. Theory Comput. 2015, 11, 4439-4449 10.1021/acs.jctc.5b00472
90. Negami, T.; Shimizu, K.; Terada, T. Coarse-grained molecular dynamics simulations of protein-ligand binding J. Comput. Chem. 2014, 35, 1835-1845 10.1002/jcc.23693
91. Kruse, A. C.; Ring, A. M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hubner, H.; Pardon, E.; Valant, C.; Sexton, P. M.; Christopoulos, A.; Felder, C. C.; Gmeiner, P.; Steyaert, J.; Weis, W. I.; Garcia, K. C.; Wess, J.; Kobilka, B. K. Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 2013, 504, 101-106 10.1038/nature12735
92. 2-like receptors Bioorg. Med. Chem. 2012, 20, 455-466 10.1016/j.bmc.2011.10.063
93. 2 receptor functionalized congeners and homobivalent ligands MedChemComm 2014, 5, 891 10.1039/c4md00066h